OTCMKTS:BMXMF bioMérieux (BMXMF) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free BMXMF Stock Alerts $105.69 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$105.69▼$105.6950-Day Range$102.85▼$113.3852-Week Range$90.23▼$115.25VolumeN/AAverage Volume54 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartShort InterestStock AnalysisAnalyst ForecastsChartShort Interest Get bioMérieux alerts: Email Address Ad WealthPressIt’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << About bioMérieux Stock (OTCMKTS:BMXMF)bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.Read More BMXMF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BMXMF Stock News HeadlinesMarch 6, 2024 | benzinga.comBiomerieux/adr's Net WorthOctober 19, 2023 | marketwatch.comOxford Nanopore Shares Rise on Backed Guidance, GBP70 Mln Investment by bioMerieuxApril 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… October 26, 2022 | msn.combioMerieux : les résultats 2022 devraient se situer dans la borne haute des intervalles publiés en aoûtApril 13, 2022 | msn.combioMerieux : du mieuxApril 12, 2022 | msn.combioMerieux recule après les annoncesMarch 3, 2022 | seekingalpha.combioMérieux S.A. GAAP EPS of €5.06, revenue of €3.37MJanuary 7, 2022 | finance.yahoo.comFrench multidisciplinary consortium ARPEGE awarded public funding of close to €9 million to fight antibiotic resistanceApril 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… October 21, 2021 | finance.yahoo.comBaxter and bioMérieux Announce CE Mark for NEPHROCLEAR™ CCL14 Test to Predict Persistent Severe Acute Kidney InjuryOctober 5, 2021 | finance.yahoo.combioMerieux to Exhibit at SupplySide West 2021 at Mandalay Bay in Las Vegas Oct. 25-28, 2021See More Headlines Receive BMXMF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bioMérieux and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:BMXMF CUSIPN/A CIKN/A Webwww.biomerieux.com Phone33-04-78-87-20-00Fax33-04-78-87-20-90Employees13,800Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$3.98 billion Price / SalesN/A Cash Flow$5.90 per share Price / Cash Flow17.92 Book Value$32.43 per share Price / Book3.26Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.87 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Pierre Boulud (Age 53)Chief Executive Officer Comp: $1.13MMr. Frederic Beseme (Age 68)Head of CSR Comp: $23.82kMr. Guillaume Bouhours (Age 48)Executive VP of Purchasing and Information Systems & CFO Sylvain MorgeauInvestor RelationsMs. Audrey Dauvet (Age 50)Executive Vice President of Legal Affairs & Integrity Ms. Valerie LeyldeExecutive Vice President of Human Resources, Communications & CSRMr. Pierre CharbonnierExecutive Vice President of Global Quality, Manufacturing & Supply ChainMr. Yasha MitrottiExecutive Vice President of Industrial ApplicationsJennifer ZinnExecutive Vice President of Clinical OperationsCharles K. CooperExecutive VP & Chief Medical OfficerMore ExecutivesKey CompetitorsDiaSorinOTCMKTS:DSRLFMDxHealthNASDAQ:MDXHPharma MarOTCMKTS:PHMMFRecordati Industria Chimica e FarmaceuticaOTCMKTS:RCDTFRespiriOTCMKTS:KMLXFView All Competitors BMXMF Stock Analysis - Frequently Asked Questions Should I buy or sell bioMérieux stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for bioMérieux in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BMXMF shares. View BMXMF analyst ratings or view top-rated stocks. How have BMXMF shares performed in 2024? bioMérieux's stock was trading at $108.50 at the beginning of 2024. Since then, BMXMF shares have decreased by 2.6% and is now trading at $105.69. View the best growth stocks for 2024 here. Are investors shorting bioMérieux? bioMérieux saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 277,300 shares, an increase of 27.7% from the March 31st total of 217,200 shares. Based on an average trading volume of 100 shares, the short-interest ratio is presently 2,773.0 days. View bioMérieux's Short Interest. How do I buy shares of bioMérieux? Shares of BMXMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BMXMF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bioMérieux S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
